How is this different from a weight loss clinic?

Written and medically reviewed by Zahraa Sater, M.D., M.P.H.

Reviewed August 12, 2026 · Next review due August 12, 2028

Short answer

A weight loss clinic usually starts with the medication and measures success in pounds lost. An endocrinologist starts with why the weight is there: thyroid function, insulin, sex hormones, sleep, and drugs that cause weight gain. Both may end up prescribing semaglutide or tirzepatide. The difference is what gets excluded first and what happens when the drug stops.

A weight loss clinic and an endocrinology practice can prescribe the same drugs, at the same doses, under the same FDA labels. What differs is the order of operations. A weight loss clinic typically confirms you meet a threshold, prescribes, and tracks the scale. An endocrinologist is trained to ask what is producing the weight before treating it, because thyroid disease, insulin resistance, PCOS, sleep apnea and a long list of ordinary medications all change weight and all have their own treatment.

What gets excluded first

The first difference appears in what is ruled out before a prescription is written. Hypothyroidism, obstructive sleep apnea and drug induced weight gain from atypical antipsychotics, lithium, valproate, some antidepressants, beta blockers, sulfonylureas, insulin, glucocorticoids and progestins are all treatable causes with answers of their own. If one of these is the driver, a GLP-1 will still lower the weight, and the driver will still be sitting there when the drug stops. The 2016 Endocrine Society guideline on pharmacological management of obesity puts diet, exercise and behavioural change in every obesity plan regardless of which medication is used.

What counts as success

The second difference is the measure. A service judged on weight alone will count muscle loss as progress. An endocrinology plan looks at where the weight came from: lean mass, waist circumference, blood pressure, HbA1c, lipids and liver enzymes, with a protein target and resistance training in place to protect muscle while the weight comes off. Zepbound is now also labelled for moderate to severe obstructive sleep apnea in adults with obesity, which is a clean example of the diagnosis, rather than the number on the scale, deciding the drug.

Where a weight loss clinic is the better choice

Weight loss clinics are not a lesser thing, and they solve a genuine access problem for people who cannot reach a specialist. If you have already had a full endocrine workup, your thyroid and sleep are documented, and what you need is supervised titration of an approved medication at a lower cost, a weight loss clinic can do that well. Two things are worth checking at the edges: whether the product is FDA approved rather than compounded, and whether anyone has written a plan for the day you stop. The FDA has published concerns about compounded GLP-1 products, including dosing errors that led to hospitalisation.

QuestionTypical weight loss clinicEndocrinology practice
What decides eligibilityBMI threshold and label contraindicationsThe same criteria, after a cause has been sought
What is excluded firstUsually a standard intake formThyroid, sleep, medication causes, insulin and sex hormones
What is measuredWeightWeight, lean mass, waist, HbA1c, lipids, blood pressure
Which productSometimes compoundedFDA approved products
Plan for stoppingOften not statedWritten before the dose is escalated

Whichever you choose, ask two questions before the first prescription is sent. What else could be causing this, and how was it ruled out? And what is the plan for maintenance once I reach the weight I am aiming for? A service that cannot answer the second question is selling a phase rather than a treatment.

The clinical detail

Label thresholds are identical wherever the prescription comes from. Wegovy is indicated for chronic weight management in adults with an initial BMI of 30 kg/m2 or greater, or 27 kg/m2 or greater with at least one weight related comorbid condition, and in patients aged 12 and over at or above the 95th percentile for age and sex. Zepbound carries the same adult BMI thresholds and is additionally indicated for moderate to severe obstructive sleep apnea in adults with obesity. Both are contraindicated in personal or family history of medullary thyroid carcinoma and in multiple endocrine neoplasia syndrome type 2.

The 2016 Endocrine Society guideline advises discontinuing a weight medication and reassessing if the patient has not lost at least 5 percent of body weight after three months at a full dose.

Written and medically reviewed by Zahraa Sater, M.D., M.P.H.

Reviewed August 12, 2026 · Next review due August 12, 2028

Sources

  1. Pharmacological Management of Obesity, clinical practice guideline. Endocrine Society
  2. WEGOVY (semaglutide) injection, prescribing information. U.S. Food and Drug Administration
  3. ZEPBOUND (tirzepatide) injection, prescribing information. U.S. Food and Drug Administration
  4. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration
  5. SURMOUNT-4: Weight Reversal Post Tirzepatide Withdrawal, journal scan. American College of Cardiology

Was this answer helpful?

This library is educational and is not individual medical advice. Read our Editorial and Medical Review Policy.